S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics

Organon & Co. (OGN) Stock Price, News & Analysis

$18.80
+0.35 (+1.90%)
(As of 03/28/2024 ET)
Today's Range
$18.43
$18.93
50-Day Range
$15.50
$18.80
52-Week Range
$10.84
$24.79
Volume
2.25 million shs
Average Volume
2.04 million shs
Market Capitalization
$4.81 billion
P/E Ratio
4.70
Dividend Yield
5.96%
Price Target
$21.80

Organon & Co. MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
16.0% Upside
$21.80 Price Target
Short Interest
Healthy
3.97% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.37
Upright™ Environmental Score
News Sentiment
1.61mentions of Organon & Co. in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$49,939 Bought Last Quarter
Proj. Earnings Growth
2.94%
From $4.08 to $4.20 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.92 out of 5 stars

Medical Sector

25th out of 938 stocks

Pharmaceutical Preparations Industry

12th out of 435 stocks

OGN stock logo

About Organon & Co. Stock (NYSE:OGN)

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

OGN Stock Price History

OGN Stock News Headlines

OGN Quantitative Stock Analysis
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Organon & Co (OGN)
Organon's Valuation Is Not Expensive
Organon Stock Is Still Worth A Look
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Organon & Co. (NYSE:OGN) Q4 2023 Earnings Call Transcript
Organon Stock (NYSE:OGN), Guidance and Forecast
Looking Into Organon's Recent Short Interest
Organon & Co (OGN) Fell on Missed Consensus
See More Headlines
Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Ex-Dividend for 3/14 Dividend
2/23/2024
Dividend Payable
3/14/2024
Today
3/29/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
10,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.80
High Stock Price Target
$28.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+16.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$1.02 billion
Pretax Margin
10.75%

Debt

Sales & Book Value

Annual Sales
$6.26 billion
Cash Flow
$5.12 per share
Book Value
($0.27) per share

Miscellaneous

Free Float
252,647,000
Market Cap
$4.81 billion
Optionable
Not Optionable
Beta
0.81
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Kevin Ali (Age 64)
    CEO & Director
    Comp: $3.96M
  • Mr. Matthew M. Walsh (Age 57)
    Executive VP & CFO
    Comp: $1.84M
  • Ms. Susanne Gabriele Fiedler (Age 56)
    Executive VP & Chief Commercial Officer
    Comp: $1.44M
  • Mr. Joseph T. Morrissey Jr. (Age 59)
    Executive VP and Head of Manufacturing & Supply
    Comp: $1.54M
  • Ms. Rachel A. Stahler (Age 48)
    Executive VP & Chief Information Officer
  • Ms. Jennifer Halchak
    Vice President of Investor Relations
  • Mr. Kirke Weaver (Age 51)
    Executive VP, General Counsel & Corporate Secretary
  • Mr. Aaron Falcione (Age 53)
    Executive VP & Chief Human Resources Officer
  • Mr. Vittorio Nisita (Age 56)
    Executive VP & Head of Global Business Services
  • Ms. Meghan Rivera
    US Managing Director

OGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Organon & Co. stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OGN shares.
View OGN analyst ratings
or view top-rated stocks.

What is Organon & Co.'s stock price target for 2024?

4 Wall Street analysts have issued 1-year price targets for Organon & Co.'s shares. Their OGN share price targets range from $18.00 to $28.00. On average, they predict the company's stock price to reach $21.80 in the next year. This suggests a possible upside of 16.0% from the stock's current price.
View analysts price targets for OGN
or view top-rated stocks among Wall Street analysts.

How have OGN shares performed in 2024?

Organon & Co.'s stock was trading at $14.42 on January 1st, 2024. Since then, OGN shares have increased by 30.4% and is now trading at $18.80.
View the best growth stocks for 2024 here
.

Are investors shorting Organon & Co.?

Organon & Co. saw a drop in short interest in the month of February. As of February 29th, there was short interest totaling 9,710,000 shares, a drop of 27.2% from the February 14th total of 13,340,000 shares. Based on an average trading volume of 3,630,000 shares, the days-to-cover ratio is currently 2.7 days. Currently, 3.8% of the shares of the company are sold short.
View Organon & Co.'s Short Interest
.

When is Organon & Co.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our OGN earnings forecast
.

How were Organon & Co.'s earnings last quarter?

Organon & Co. (NYSE:OGN) announced its earnings results on Thursday, February, 15th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.14. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a net margin of 16.33% and a negative trailing twelve-month return on equity of 212.00%.

How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?

Organon & Co. declared a quarterly dividend on Thursday, February 15th. Shareholders of record on Monday, February 26th will be paid a dividend of $0.28 per share on Thursday, March 14th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 5.96%. The ex-dividend date of this dividend is Friday, February 23rd.
Read our dividend analysis for OGN
.

Is Organon & Co. a good dividend stock?

Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 6.07%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 28.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 26.67% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for OGN.

What guidance has Organon & Co. issued on next quarter's earnings?

Organon & Co. issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $6.2 billion-$6.5 billion, compared to the consensus revenue estimate of $6.4 billion.

Who are Organon & Co.'s major shareholders?

Organon & Co.'s stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.97%), Vanguard Group Inc. (11.97%), Massachusetts Financial Services Co. MA (3.99%), Sound Shore Management Inc. CT (1.83%), LSV Asset Management (1.31%) and Point72 Asset Management L.P. (1.25%). Insiders that own company stock include Kirke Weaver and Ma Fatima Francisco.
View institutional ownership trends
.

How do I buy shares of Organon & Co.?

Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:OGN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners